MDSpire - Summary
Feature

AI As Collaborator in Cancer Research and in Clinical Care

Last October, the Cancer AI Alliance (CAIA) announced the launch of its collaborative artificial intelligence (AI) platform powered by federated learning to train AI models with millions of de-identif...

Share

Eliezer Van Allen, MD, leads the Cancer AI Alliance (CAIA), which launched a collaborative AI platform utilizing federated learning to safely analyze extensive de-identified datasets from four major cancer centers. This initiative aims to enhance precision cancer care by addressing data silos and ensuring broader data access for improved research insights. With eight pilot projects underway, CAIA investigates complex questions in oncology, striving to personalize cancer treatment and advance equity in patient care amid historical challenges in data sharing.

Original Source(s)

AI As Collaborator in Cancer Research and in Clinical Care

  • by Jo Cavallo

  • March 26, 2026

Related Content

AI Use in Cancer Diagnosis, Prognosis, and Treatment: Are We There Yet?

The promise of artificial intelligence (AI) technologies to provide highly personalized oncology care for patients and improve outcomes has been decades in the making. In a 1987 editorial in The New E...

Roswell Park Faculty to Present at National Comprehensive Cancer Network 2026 Annual Conference

Clinical researchers from Roswell Park Comprehensive Cancer Center are among the experts invited to share insights and clinical best practices at the National Comprehensive Cancer Network (NCCN) 2026 Annual Conference March 27-29 in Orlando, Florida.

  • by

  • March 26, 2026

  • 3 min
Stanford Names Leader for Drug Development and Precision Oncology

Vivek Subbiah, MD, has been appointed as the inaugural associate director for drug development and precision oncology at the Stanford Cancer Institute, with a planned start date in spring 2026. In thi...